CVS Health shares surged 7.65% following a strong Q1 2026 earnings report, beating EPS estimates with $2.57 adjusted EPS and 6.2% revenue growth to $100.4 billion. The key driver was Aetna's 52.6% jump in adjusted operating income and improved medical benefit ratio, prompting management to raise full-year EPS guidance to $7.30-$7.50. Analysts are bullish, with price targets raised to around $100 and a 24/7 Wall St. target of $125.45, implying 44% upside. Risks include pharmacy reimbursement pressures and regulatory drug price cuts, but the overall outlook is positive if Aetna's margin recovery continues.
CVS Health has sold its Omnicare long-term care pharmacy network to GenieRx for $250 million, following approval from a bankruptcy court. The sale is part of CVS's strategy to concentrate on more profitable areas after Omnicare underperformed and fac...
CVS Health and WGU have partnered to offer an online pre-pharmacy Associate of Science degree aimed at reducing financial barriers for CVS employees pursuing pharmacy careers. The program provides flexible, affordable coursework with tuition assistan...
The U.S. Bankruptcy Court approved the sale of Omnicare, a CVS Health subsidiary providing pharmacy services to long-term care facilities, to GenieRx Holdings LLC, a partnership of Milrose Capital and Integro Healthcare Services. This sale marks a ne...
MinuteClinic, located in select CVS Pharmacy stores across 49 states and D.C., offers a clinically supervised weight-loss program available seven days a week, including evenings and weekends, through both in-person and virtual visits. The program has...
